Psoriatic arthritis, a chronic skin condition that affects patients on physically and mentally – often impacts patients’ mobility in their daily lives. Healthcare professionals across all specialties have experience when dealing with these patients in different capacities.
New analysis of data from longitudinal cohorts finds that psoriatic arthritis patients were more than 50% more likely than those with psoriasis but no arthritis to develop infection. It also provides further evidence that biologic medications are also a risk factor for infection.
Connective tissue disease (CTD) groups together various disorders, such as rheumatoid arthritis and lupus. A new study from the University of Chicago found that complications from these diseases are more prominent based on race.
Blood analysis in patients with inflammatory rheumatic diseases such as psoriatic arthritis indicates that biologic medications do not reduce the efficacy of anti-pneumococcal polysaccharide vaccine, and that patients with such conditions may not need to be vaccinated more frequently than others.
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).